The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China
OBJECTIVE: In order to fight against coronavirus disease 2019 (COVID-19) better and to share our experience as a reference for clinical laboratory departments. METHODS: This was a retrospective study conducted in the clinical laboratory department of Chengdu Women’s and Children’s Central Hospital i...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505680/ https://www.ncbi.nlm.nih.gov/pubmed/34675712 http://dx.doi.org/10.2147/RMHP.S323605 |
_version_ | 1784581584427417600 |
---|---|
author | Wang, Qin Liu, Chenggui Xu, Jian Song, Peipei Yang, Shuzhe Zhang, Qin |
author_facet | Wang, Qin Liu, Chenggui Xu, Jian Song, Peipei Yang, Shuzhe Zhang, Qin |
author_sort | Wang, Qin |
collection | PubMed |
description | OBJECTIVE: In order to fight against coronavirus disease 2019 (COVID-19) better and to share our experience as a reference for clinical laboratory departments. METHODS: This was a retrospective study conducted in the clinical laboratory department of Chengdu Women’s and Children’s Central Hospital in Chengdu, China, from April 2020 to January 2021. The number of nucleic acid and antibody testing specimens of suspected COVID-19 cases was analyzed. The key points of suspected-case sample processing and detection in the clinical laboratory department were summarized. The laboratory was directly involved in the sample processing and testing of suspected cases, the release of reports, and the transfer of specimens to the fever clinic. RESULTS: The number of COVID-19 nucleic acid test specimens in our laboratory ranged from 102 to 2170 per day, and the number of antibody test specimens ranged from 24 to 391 per day. There were four main considerations in the treatment and detection of suspected-case specimens in the clinical laboratory: biosafety management in clinical laboratory departments, measures to ensure the health of the staff, the eight time points for processing suspected-case samples (turn-around time), and key points for the detection of suspected case specimens. CONCLUSION: The laboratory developed a protective process for COVID-19 antibody and nucleic acid detection during the pandemic. At present, the detection of COVID-19 antibodies and nucleic acids in the clinical laboratory department is orderly, and there have been no cases of laboratory infection. |
format | Online Article Text |
id | pubmed-8505680 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-85056802021-10-20 The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China Wang, Qin Liu, Chenggui Xu, Jian Song, Peipei Yang, Shuzhe Zhang, Qin Risk Manag Healthc Policy Perspectives OBJECTIVE: In order to fight against coronavirus disease 2019 (COVID-19) better and to share our experience as a reference for clinical laboratory departments. METHODS: This was a retrospective study conducted in the clinical laboratory department of Chengdu Women’s and Children’s Central Hospital in Chengdu, China, from April 2020 to January 2021. The number of nucleic acid and antibody testing specimens of suspected COVID-19 cases was analyzed. The key points of suspected-case sample processing and detection in the clinical laboratory department were summarized. The laboratory was directly involved in the sample processing and testing of suspected cases, the release of reports, and the transfer of specimens to the fever clinic. RESULTS: The number of COVID-19 nucleic acid test specimens in our laboratory ranged from 102 to 2170 per day, and the number of antibody test specimens ranged from 24 to 391 per day. There were four main considerations in the treatment and detection of suspected-case specimens in the clinical laboratory: biosafety management in clinical laboratory departments, measures to ensure the health of the staff, the eight time points for processing suspected-case samples (turn-around time), and key points for the detection of suspected case specimens. CONCLUSION: The laboratory developed a protective process for COVID-19 antibody and nucleic acid detection during the pandemic. At present, the detection of COVID-19 antibodies and nucleic acids in the clinical laboratory department is orderly, and there have been no cases of laboratory infection. Dove 2021-10-07 /pmc/articles/PMC8505680/ /pubmed/34675712 http://dx.doi.org/10.2147/RMHP.S323605 Text en © 2021 Wang et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Perspectives Wang, Qin Liu, Chenggui Xu, Jian Song, Peipei Yang, Shuzhe Zhang, Qin The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China |
title | The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China |
title_full | The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China |
title_fullStr | The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China |
title_full_unstemmed | The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China |
title_short | The Experience of the Fight Against COVID-19 in Clinical Laboratory Departments from Chengdu, China |
title_sort | experience of the fight against covid-19 in clinical laboratory departments from chengdu, china |
topic | Perspectives |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8505680/ https://www.ncbi.nlm.nih.gov/pubmed/34675712 http://dx.doi.org/10.2147/RMHP.S323605 |
work_keys_str_mv | AT wangqin theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT liuchenggui theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT xujian theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT songpeipei theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT yangshuzhe theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT zhangqin theexperienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT wangqin experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT liuchenggui experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT xujian experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT songpeipei experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT yangshuzhe experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina AT zhangqin experienceofthefightagainstcovid19inclinicallaboratorydepartmentsfromchengduchina |